Merrimack Pharmaceuticals (MACK) Getting Somewhat Positive News Coverage, Accern Reports
Headlines about Merrimack Pharmaceuticals (NASDAQ:MACK) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Merrimack Pharmaceuticals earned a news impact score of 0.05 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.921024198882 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of Merrimack Pharmaceuticals (NASDAQ MACK) opened at 1.32 on Friday. The company’s 50-day moving average price is $1.30 and its 200 day moving average price is $2.38. The company has a market cap of $175.29 million, a P/E ratio of 0.41 and a beta of 2.02. Merrimack Pharmaceuticals has a one year low of $1.13 and a one year high of $6.79.
Merrimack Pharmaceuticals (NASDAQ:MACK) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by $0.08. During the same period in the prior year, the firm posted ($0.40) earnings per share. On average, equities research analysts anticipate that Merrimack Pharmaceuticals will post $3.36 earnings per share for the current year.
MACK has been the subject of several recent research reports. Zacks Investment Research upgraded Merrimack Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, May 15th. Cowen and Company restated a “market perform” rating on shares of Merrimack Pharmaceuticals in a report on Friday, May 19th. Finally, ValuEngine downgraded Merrimack Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $7.09.
COPYRIGHT VIOLATION NOTICE: This piece was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/26/merrimack-pharmaceuticals-mack-getting-somewhat-positive-news-coverage-accern-reports.html.
Merrimack Pharmaceuticals Company Profile
Merrimack Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development.
Receive News & Stock Ratings for Merrimack Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.